Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Schedule an appointment.
Retrieved from Seghier, M
Phase 3 trials are ongoing and will provide more definitive efficacy and safety data
It cites clinical trial data for its molecules (15 to 20% for semaglutide, 20 to 22% for tirzepatide from SURMOUNT-1 and STEP)
The hazard ratio and 95% confidence interval did not reveal a significant difference between tirzepatide or insulin glargine treatment (HR, 0.74
Patients may experience a temporary increase in gastrointestinal symptoms with each dose increase, though these usually resolve within one to two weeks
US$ 29.66
US$ 27.71
US$ 23.67
US$ 22.26
